InChI=1S/C109H188N16O22S/c1- 4- 7- 10- 13- 16- 19- 22- 25- 28- 31- 34- 37- 40- 63- 92(130) 115- 88(78- 148- 77- 80(146- 95(133) 65- 42- 39- 36- 33- 30- 27- 24- 21- 18- 15- 12- 9- 6- 3) 76- 145- 94(132) 64- 41- 38- 35- 32- 29- 26- 23- 20- 17- 14- 11- 8- 5- 2) 106(140) 120- 87(74- 126) 105(139) 119- 86(61- 50- 54- 70- 113) 104(138) 118- 85(60- 49- 53- 69- 112) 103(137) 117- 84(59- 48- 52- 68- 111) 102(136) 116- 83(58- 47- 51- 67- 110) 101(135) 114- 71- 66- 93(131) 124- 73- 79- 55- 43- 44- 56- 81(79) 96- 98(82- 57- 45- 46- 62- 89(82) 124) 125(123- 122- 96) 108(143) 121- 97- 90(128) 72- 109(144,107(141) 142) 147- 100(97) 99(134) 91(129) 75- 127/h43- 46,55- 57,62,80,83- 88,90- 91,96- 100,126- 129,134,144H,4- 42,47- 54,58- 61,63- 78,110- 113H2,1- 3H3,(H,114,135) (H,115,130) (H,116,136) (H,117,137) (H,118,138) (H,119,139) (H,120,140) (H,121,143) (H,141,142) /t80?,83- ,84- ,85- ,86- ,87- ,88- ,90+,91- ,96?,97- ,98?,99- ,100- ,109+/m1/s1 |
HACHPVCYFLSKSB-UMJDSZQGSA-N |
[H] [C@] 1(O[C@@] (O) (C[C@H] (O) [C@H] 1NC(=O) N1N=NC2C1C1=CC=CC=C1N(CC1=C2C=CC=C1) C(=O) CCNC(=O) [C@@H] (CCCCN) NC(=O) [C@@H] (CCCCN) NC(=O) [C@@H] (CCCCN) NC(=O) [C@@H] (CCCCN) NC(=O) [C@@H] (CO) NC(=O) [C@@H] (CSCC(COC(=O) CCCCCCCCCCCCCCC) OC(=O) CCCCCCCCCCCCCCC) NC(=O) CCCCCCCCCCCCCCC) C(O) =O) [C@H] (O) [C@H] (O) CO |
|
neoantigen
A mainly tumour-specific antigen generated by mutations in tumour cells. Neoantigens are only expressed in tumour cells.
epitope
The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.
|
|
View more via ChEBI Ontology
5- {[8- (3- {[(2R)- 6- amino- 2- {[(2R)- 6- amino- 2- {[(2R)- 6- amino- 2- ({S- [2,3- bis(hexadecanoyloxy)propyl]- N- hexadecanoyl- D- cysteinyl- D- seryl- D- lysyl}amino)hexanoyl]amino}hexanoyl]amino}hexanoyl]amino}propanoyl)- 3a,8,9,13b- tetrahydro- 3H- dibenzo[b,f][1,2,3]triazolo[4,5- d]azocine- 3- carbonyl]amino}- 3,5- dideoxy- D- glycero- β- D- galacto- non- 2- ulopyranosonic acid
|
34158858
|
PubMed citation
|
Europe PMC
|
|